🇺🇸 FDA
Patent

US 8648072

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

granted A61PA61P1/16A61P29/00

Quick answer

US patent 8648072 (Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes) held by Jenrin Discovery, LLC expires Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Jenrin Discovery, LLC
Grant date
Tue Feb 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P1/16, A61P29/00, A61P3/04, A61P3/06